PHARMACY

Metcare physicians granted access to Informed Decisions’ eMPOWERx

BY Drew Buono

TAMPA, Fla. The drug information company Informed Decisions and the healthcare organization Metcare of Florida, a wholly owned subsidiary of Metropolitan Health Networks, have entered into an agreement to deploy eMPOWERx, Informed Decisions’ electronic prescribing and patient care system, to physicians in Metcare’s provider services network.

Under the agreement, participating physicians will utilize eMPOWERx for eprescribing, as well as to access integrated drug information, drug-drug interaction screening tools and real-time patient medication histories. Physicians will have point-of-care access by using wireless tablet computers to connect to the secure eMPOWERx website.

“By deploying eMPOWERx, Metcare is providing its physicians with more than just e-prescribing capabilities. It is arming them with clinical decision support tools and an unprecedented depth of drug information that will result in more informed care decisions, better coordination of care, reduced costs, and improved health outcomes,” said Kathy Mosbaugh, executive vice president, Informed Decisions.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

ImClone to pay $17.5 million to Abbott in Erbitux settlement

BY Drew Buono

BOSTON ImClone Systems, manufacturer of the cancer drug Erbitux, has agreed to pay Abbott Laboratories $17.5 million to end a patent-infringement lawsuit over the medicine, according to Bloomberg.

The companies said in an Aug. 4 notice to U.S. District Judge Richard Stearns in Boston that they had reached a “confidential settlement.” Stearns put the case on hold so the companies can finish the paperwork on the agreement.

Abbott sued ImClone last year, claiming its patented method for creating antibodies is infringed by Erbitux. In May, ImClone filed a lawsuit accusing Abbott of withholding information that could have been used by ImClone to defend itself against a patent suit by Repligen. ImClone paid $65 million to end that case.

“We have reached an agreement in principle that would conclude all outstanding litigation with ImClone,” said Abbott spokesman Scott Stoffel.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA warns about muscle damage from drug combo

BY Alaric DeArment

WASHINGTON Combining some heart drugs could cause muscular damage, Reuters reported the Food and Drug Administration as warning.

The FDA said it had received reports of the muscle injury rhabdomyolysis, which can cause kidney failure or death, related to combining the cholesterol drug simvastatin and the arrythmia drug amiodarone. The agency issued a warning about the risks of combining the drugs in 2002.

All statin drugs have the risk of causing rhabdomyolysis, but the risk becomes greater when simvastatin is combined with amiodarone.

Simvastatin is the active ingredient in Merck’s Simcor and Abbott Laboratories’ Zocor, as well as an ingredient in Merck’s and Schering-Plough’s Vytorin. Amiodarone is the active ingredient in Wyeth’s Cordarone and Upsher-Smith’s Pacerone.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?